All Stories

  1. Nanoparticles may influence mast cells gene expression profiles without affecting their degranulation function

    Article • Nanomedicine Nanotechnology Biology and Medicine, June 2025, Elsevier

    Neill Liptrott

  2. Redefining LNP composition: phospholipid and sterol-driven modulation of mRNA expression and immune outcomes

    Article • RSC Pharmaceutics, January 2025, Royal Society of Chemistry

    Neill Liptrott

  3. Nano(bio)Materials Do Not Affect Macrophage Phenotype—A Study Conducted by the REFINE Project

    Article • International Journal of Molecular Sciences, May 2024, MDPI AG

    Neill Liptrott

  4. Nano(bio)materials Do Not Affect Macrophage Phenotype – A Study Conducted by the REFINE Project

    Article • May 2024, MDPI AG

    Neill Liptrott

  5. In vitro evaluation of physicochemical-dependent effects of polymeric nanoparticles on their cellular uptake and co-localization using pulmonary calu-3 cell lines

    Article • Drug Development and Industrial Pharmacy, March 2024, Taylor & Francis

    Neill Liptrott

  6. Interlaboratory comparison of endotoxin contamination assessment of nanomaterials

    Article • Nanoscale, January 2024, Royal Society of Chemistry

    Neill Liptrott

  7. Age-differential CD13 and interferon expression in airway epithelia affect SARS-CoV-2 infection - Effects of vitamin D

    Article • Mucosal Immunology, December 2023, Elsevier

    Neill Liptrott

  8. Umbilical cord mesenchymal stromal cell-derived extracellular vesicles lack the potency to immunomodulate human monocyte-derived macrophages in vitro

    Article • Biomedicine & Pharmacotherapy, November 2023, Elsevier

    Neill Liptrott

  9. Late Breaking Abstract - Age and vitamin D influence airway epithelial cells response to SARS-CoV-2 infection

    Article • September 2023, European Respiratory Society (ERS)

    Neill Liptrott

  10. Intravenous Administration of Human Umbilical Cord Mesenchymal Stromal Cells Leads to an Inflammatory Response in the Lung

    Article • Stem Cells International, September 2023, Wiley

    Neill Liptrott

  11. Application of KU812 cells for assessing complement activation related effects by nano(bio)materials

    Article • Biomedicine & Pharmacotherapy, July 2023, Elsevier

    Neill Liptrott

  12. Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations

    Article • Pharmaceutics, June 2023, MDPI AG

    Neill Liptrott

  13. Fate of intravenously administered umbilical cord mesenchymal stromal cells and interactions with the host's immune system

    Article • Biomedicine & Pharmacotherapy, March 2023, Elsevier

    Neill Liptrott

  14. Polymer–prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine

    Article • Journal of Materials Chemistry B, January 2023, Royal Society of Chemistry

    Neill Liptrott

  15. Exposure of the Basophilic Cell Line KU812 to Liposomes Reveals Activation Profiles Associated with Potential Anaphylactic Responses Linked to Physico-Chemical Characteristics

    Article • Pharmaceutics, November 2022, MDPI AG

    Neill Liptrott

  16. Intravenous administration of human umbilical cord mesenchymal stromal cells leads to an inflammatory response in the lung

    Article • September 2022, openRxiv

    Neill Liptrott

  17. An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars

    Article • Drug Delivery and Translational Research, July 2022, Springer Science + Business Media

    Neill Liptrott

  18. Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1

    Article • Biomedicine & Pharmacotherapy, June 2022, Elsevier

    Neill Liptrott

  19. Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances

    Article • Drug Delivery and Translational Research, May 2022, Springer Science + Business Media

    Neill Liptrott

  20. PBPK Modelling for Intratumoral Biodistribution of Magnetic Iron Oxide Nanoparticles

    Article • April 2022, Avestia Publishing

    Neill Liptrott

  21. Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants

    Article • Journal of Materials Chemistry B, January 2022, Royal Society of Chemistry

    Neill Liptrott

  22. Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19

    Article • Advanced Drug Delivery Reviews, November 2021, Elsevier

    Neill Liptrott

  23. Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation

    Article • Journal of Controlled Release, August 2021, Elsevier

    Neill Liptrott

  24. Firefly luciferase offers superior performance to AkaLuc for tracking the fate of administered cell therapies

    Article • European Journal of Pediatrics, July 2021, Springer Science + Business Media

    Neill Liptrott

  25. Assessment of changes in autophagic vesicles in human immune cell lines exposed to nano particles

    Article • Cell & Bioscience, July 2021, Springer Science + Business Media

    Neill Liptrott

  26. AUTOSTERE: Systematic Search for Scaffold Replacement Opportunities within Structural Databases

    Article • Journal of Chemical Information and Modeling, April 2021, American Chemical Society (ACS)

    Neill Liptrott

  27. Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection

    Article • January 2021, American Chemical Society (ACS)

    James Hobson, Neill Liptrott

  28. Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection

    Article • January 2021, American Chemical Society (ACS)

    James Hobson, Neill Liptrott

  29. Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier

    Article • Molecules, January 2021, MDPI AG

    Neill Liptrott

  30. Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection

    Article • Nanoscale, January 2021, Royal Society of Chemistry

    James Hobson, Neill Liptrott

  31. Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis

    Article • British Journal of Clinical Pharmacology, December 2020, Wiley

    Neill Liptrott

  32. In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear Cells

    Article • International Journal of Molecular Sciences, August 2020, MDPI AG

    Neill Liptrott

  33. Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

    Article • Clinical Pharmacology & Therapeutics, June 2020, Wiley

    Neill Liptrott

  34. Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected, drug-free anticoagulant activity

    Article • Nanomedicine, June 2020, Future Medicine

    James Hobson, Neill Liptrott

  35. Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis

    Article • May 2020, Wiley

    Neill Liptrott

  36. Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

    Article • May 2020, openRxiv

    Neill Liptrott

  37. Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics

    Article • April 2020, openRxiv

    Neill Liptrott

  38. Critical considerations for targeting colorectal liver metastases with nanotechnology

    Article • Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, September 2019, Wiley

    Neill Liptrott

  39. Immunotoxicity Considerations for Next Generation Cancer Nanomedicines

    Article • Advanced Science, August 2019, Wiley

    Neill Liptrott

  40. Bridging communities in the field of nanomedicine

    Article • Regulatory Toxicology and Pharmacology, August 2019, Elsevier

    Neill Liptrott

  41. Long-Acting Injectable Statins—Is It Time for a Paradigm Shift?

    Article • Molecules, July 2019, MDPI AG

    Neill Liptrott

  42. Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies

    Article • Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, December 2018, Wiley

    Neill Liptrott

  43. Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems

    Article • Journal of Nanobiotechnology, March 2018, Springer Science + Business Media

    Neill Liptrott

  44. Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach

    Article • Drug Metabolism and Pharmacokinetics, March 2018, Elsevier

    Neill Liptrott

  45. Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates

    Article • Pharmacology Research & Perspectives, September 2017, Wiley

    Neill Liptrott

  46. Advances in nanomedicine drug delivery applications for HIV therapy

    Article • Future Science OA, September 2017, Future Science

    Neill Liptrott

  47. Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system

    Article • Nanomedicine, September 2017, Future Medicine

    Neill Liptrott

  48. In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line

    Article • Journal of Interdisciplinary Nanomedicine, September 2017, Wiley

    Professor Steven P Rannard, Dr David Dickens, Neill Liptrott, Alison Savage, James Hobson

  49. Functionalized superparamagnetic iron oxide nanoparticles provide highly efficient iron-labeling in macrophages for magnetic resonance–based detection in vivo

    Article • Cytotherapy, April 2017, Elsevier

    Neill Liptrott

  50. Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines

    Article • Nanotoxicology, January 2017, Taylor & Francis

    Neill Liptrott

  51. Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico , In Vitro , and In Vivo Investigation

    Article • Antimicrobial Agents and Chemotherapy, January 2017, ASM Journals

    Neill Liptrott

  52. Use of mRNA suppression to estimate CYP3A4 protein degradation rate constant in primary human hepatocytes

    Article • Drug Metabolism and Pharmacokinetics, January 2017, Elsevier

    Neill Liptrott

  53. Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies

    Article • Nature Communications, October 2016, Springer Science + Business Media

    Neill Liptrott

  54. Towards a rational design of solid drug nanoparticles with optimised pharmacological properties

    Article • Journal of Interdisciplinary Nanomedicine, September 2016, Wiley

    Professor Steven P Rannard, Neill Liptrott

  55. Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV- infected individuals with lymphoma

    Article • HIV Clinical Trials, July 2016, Taylor & Francis

    Neill Liptrott

  56. Determining the Relationship between Nanoparticle Characteristics and Immunotoxicity: Key Challenges and Approaches

    Article • Nanomedicine, May 2016, Taylor & Francis

    Neill Liptrott

  57. Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles

    Article • Toxicology Letters, March 2016, Elsevier

    Neill Liptrott

  58. Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery

    Article • February 2016, World Scientific Pub Co Pte Lt

    Neill Liptrott

  59. Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions

    Article • Nanomedicine, May 2015, Future Medicine

    Neill Liptrott

  60. Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter

    Article • Frontiers in Pharmacology, April 2015, Frontiers

    Neill Liptrott

  61. The Application of Nanotechnology to Drug Delivery in Medicine

    Article • January 2015, Elsevier

    Neill Liptrott

  62. Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a ‘mixed matrix’

    Article • Nanomedicine, November 2014, Future Medicine

    Dr Daniel James Nieves, Neill Liptrott

  63. Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2In Vitro

    Article • Antimicrobial Agents and Chemotherapy, September 2013, ASM Journals

    Neill Liptrott

  64. Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro-In Vivo Correlation

    Article • Advanced Healthcare Materials, September 2013, Wiley

    Tom McDonald, Neill Liptrott

  65. Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation

    Article • Journal of Antimicrobial Chemotherapy, June 2013, Oxford University Press (OUP)

    Neill Liptrott

  66. Research Spotlight: Nanomedicines for HIV therapy

    Article • Therapeutic Delivery, February 2013, Future Science

    Tom McDonald, Neill Liptrott

  67. High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli

    Article • Journal of Materials Chemistry B, January 2013, Royal Society of Chemistry

    Tom McDonald, Neill Liptrott

  68. Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

    Article • Pharmacogenetics and Genomics, January 2012, Wolters Kluwer Health

    Neill Liptrott

  69. IFN-γ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV+ Patients

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, December 2011, Wolters Kluwer Health

    Neill Liptrott

  70. Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, December 2011, Wolters Kluwer Health

    Neill Liptrott

  71. Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction

    Article • The Journal of Infectious Diseases, July 2011, Oxford University Press (OUP)

    Neill Liptrott, Dr. Vicente Soriano

  72. The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?

    Article • Expert Opinion on Drug Metabolism & Toxicology, February 2011, Informa Healthcare

    Neill Liptrott

  73. Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir

    Article • Antimicrobial Agents and Chemotherapy, November 2010, ASM Journals

    Neill Liptrott

  74. Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients

    Article • Antimicrobial Agents and Chemotherapy, October 2010, ASM Journals

    Neill Liptrott

  75. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

    Article • Pharmacogenetics and Genomics, February 2010, Wolters Kluwer Health

    Neill Liptrott

  76. The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC

    Article • British Journal of Pharmacology, February 2009, Wiley

    Neill Liptrott

  77. Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry

    Article • Journal of Immunological Methods, December 2008, Elsevier

    Neill Liptrott

  78. Handbook of Immunological Properties of Engineered Nanomaterials

    Article • World Scientific Pub Co Pte Lt

    Alessandro Parodi, Neill Liptrott